STARTUP PROFILE

Subsense Inc

COUNTRY
USA
FOUNDED
2024
CATEGORY
Brain-Computer Interface
Developing the first non-surgical, nanoparticle-based bidirectional BCI, enabling precise brain stimulation and recording without surgery.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series A
MODALITY
Others
FORM FACTOR
Implant
INTERFACE DEPTH
Minimally invasive
INDICATION
Multi-indication
TARGET USER
Patients
REGULATORY STAGE
Preclinical
Subsense is one of the more speculative BCI entrants, proposing a nanoparticle-based, non-surgical bidirectional interface that would bypass conventional implant limitations. If feasible it would be category-defining, but at present it sits firmly in high-risk frontier science.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
10
Neurotech Has Arrived
15 September – 29 September 2026

Subsense announced an expansion of its AI-driven NanoBCI strategy. The Palo Alto company is using AI and physics-based modeling to identify nanoparticle architectures before synthesis, and recently appointed Ray Kurzweil as product and vision advisor.

Articles featuring
Subsense Inc